Bright Minds Biosciences Stock (NASDAQ:DRUG)
Previous Close
$1.17
52W Range
$0.93 - $2.39
50D Avg
$1.09
200D Avg
$1.35
Market Cap
$5.09M
Avg Vol (3M)
$104.19K
Beta
1.68
Div Yield
-
DRUG Company Profile
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
DRUG Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
VIRI | Virios Therapeutics, Inc. |
PHIO | Phio Pharmaceuticals Corp. |
ADTX | Aditxt, Inc. |
REVB | Revelation Biosciences, Inc. |
RNAZ | TransCode Therapeutics, Inc. |
DRMA | Dermata Therapeutics, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
CYTO | Altamira Therapeutics Ltd. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
PYXS | Pyxis Oncology, Inc. |
UNCY | Unicycive Therapeutics, Inc. |
ZURA | Zura Bio Limited |
ELEV | Elevation Oncology, Inc. |